ReviewAllergy, asthma & immunology research2016
Using Periostin as a Biomarker in the Treatment of Asthma.
Review in Allergy, asthma & immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 92 citations in OpenAlex.
- Effect of atorvastatin on serum periostin and blood eosinophils in asthma - a placebo-controlled randomized clinical trial.The Journal of international medical research · 2021Trial
- Serum Periostin as a Biomarker in Pediatric Asthma: Findings from a Case-Control Study - Correspondence.Indian journal of pediatrics · 2026Article
- The Effect on Vitamin D Levels and VDR Gene Polymorphism on Clinical Outcomes in Asthma.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Article
- The Past, the Present, and the Future of Periostin in Allergy.Allergy, asthma & immunology research · 2026Review
- Respiratory Biomarkers: An Opportunity for Patient-Centric Microsampling Approach for Treatment Optimization.Clinical and translational science · 2026Review
- Unsupervised Phenotyping of Asthma: Integrating Serum Periostin with Clinical and Inflammatory Profiles.Diagnostics (Basel, Switzerland) · 2025Article
- Inflammation in Asthma: Mechanistic Insights and the Role of Biologics in Therapeutic Frontiers.Biomedicines · 2025Review
- Clinical perspective on serum periostin in antineutrophil-cytoplasmic antibody-associated vasculitis.The Korean journal of internal medicine · 2025Article
- Specific microRNA Profile Associated with Inflammation and Lipid Metabolism for Stratifying Allergic Asthma Severity.International journal of molecular sciences · 2024Article
- Exploring Inflammatory Asthma Phenotypes: Proteomic Signatures in Serum and Induced Sputum.International journal of molecular sciences · 2024Article
- Development of a top-down MS assay for specific identification of human periostin isoforms.Frontiers in molecular biosciences · 2024Article
- T helper 2 cells in asthma.The Journal of experimental medicine · 2023Review
- Pericytes: The lung-forgotten cell type.Frontiers in physiology · 2023Review
- Periostin as an important biomarker of inflammatory phenotype T2 in Brazilian asthma patients.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023Article
- IL13 and periostin in active fibrogenic areas of the extrahepatic bile ducts in biliary atresia patients.Pediatric surgery international · 2022Article
- Risk of fractures in individuals with eosinophilic esophagitis: nationwide population-based cohort study.Esophagus : official journal of the Japan Esophageal Society · 2022Article
- Elevated serum periostin levels among arsenic-exposed individuals and their associations with the features of asthma.Chemosphere · 2022Article
- Article
- Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach.Frontiers in allergy · 2022Article
- A review of recent advances in exosomes and allergic rhinitis.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periostin acts both as an extracellular matrix protein belonging to the fasciclin family and as a matricellular protein functioning in cell activation by binding to its receptors on the cell surface. It has been established that periostin is a downstream molecule of interleukin (IL)-13, a signature type 2 cytokine, and that periostin plays an important role in the pathogenesis of allergic diseases, including asthma. Based on these findings, much attention has been paid to periostin as a biomarker useful in the treatment of asthma. Periostin is a surrogate biomarker for type 2 immunity; it has been shown that serum periostin can predict the efficacy of anti-IL-13 antibodies (lebrikizumab) and anti-IgE antibodies (omalizumab), and that this usefulness can be potentially expanded to other type 2 antagonists. Moreover, it has been shown that periostin is not a simple surrogate biomarker for type 2 immunity; periostin-high asthma patients have several unique characteristics, including eosinophilia, high fraction of nitric oxide, aspirin intolerance, nasal disorders, and late onset. These characteristics are likely to be correlated with the involvement of periostin in the tissue remodeling of asthma. Periostin is also associated with hyporesponsiveness to inhaled corticosteroids, probably reflecting tissue remodeling. Thus, periostin has 2 characteristics as a biomarker for early diagnosis of asthma: surrogate biomarkers for type 2 immunity and tissue remodeling. Based on these characteristics, we will be able to apply serum periostin to treatment of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.